Dendritic cell dysfunction as accessory cell in patients with rheumatoid arthritis.

Imai, F; Suzuki, Tomohiko; Ishibashi, Toshiko; Katagiri, T; Akiyama, Yuji

doi:10.2177/jsci.17.7

Cited by 3 publications

(1 citation statement)

References 17 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Therefore, DMARDs have been used for SS based on their effects on other autoimmune diseases, such as SLE and RA [ 187 ]. Conventional drugs for RA are methotrexate (MTX), sulfasalazine, azathioprine, cyclosporine A (CyA), leflunomide, and hydroxychloroquine (HCQ) [ 188 , 189 , 190 , 191 , 192 ]. A pilot study on the efficacy and safety of MTX, administered at 0.2 mg/kg body weight once a week for one year, showed that subjective parameters, such as dryness of the eyes and mouth, were ameliorated; no improvements were observed in objective measures of dryness of the eyes and mouth (Schirmer’s test, the saliva flow rate).…”

Section: Treatment With Anti-rheumatic Drugsmentioning

confidence: 99%

Outline of Salivary Gland Pathogenesis of Sjögren’s Syndrome and Current Therapeutic Approaches

Yura

Hamada

2023

IJMS

View full text Add to dashboard Cite

Sjögren’s syndrome (SS) is an autoimmune disease characterized by the involvement of exocrine glands such as the salivary and lacrimal glands. The minor salivary glands, from which tissue samples may be obtained, are important for the diagnosis, evaluation of therapeutic efficacy, and genetic analyses of SS. In the onset of SS, autoantigens derived from the salivary glands are recognized by antigen-presenting dendritic cells, leading to the activation of T and B cells, cytokine production, autoantibody production by plasma cells, the formation of ectopic germinal centers, and the destruction of salivary gland epithelial cells. A recent therapeutic approach with immune checkpoint inhibitors for malignant tumors enhances the anti-tumor activity of cytotoxic effector T cells, but also induces SS-like autoimmune disease as an adverse event. In the treatment of xerostomia, muscarinic agonists and salivary gland duct cleansing procedure, as well as sialendoscopy, are expected to ameliorate symptoms. Clinical trials on biological therapy to attenuate the hyperresponsiveness of B cells in SS patients with systemic organ involvement have progressed. The efficacy of treatment with mesenchymal stem cells and chimeric antigen receptor T cells for SS has also been investigated. In this review, we will provide an overview of the pathogenesis of salivary gland lesions and recent trends in therapeutic approaches for SS.

show abstract

Section: Treatment With Anti-rheumatic Drugsmentioning

confidence: 99%

Outline of Salivary Gland Pathogenesis of Sjögren’s Syndrome and Current Therapeutic Approaches

Yura

Hamada

2023

IJMS

View full text Add to dashboard Cite

show abstract

Decreased concanavalin A-stimulated T cell proliferation in patients with Sjögren’s syndrome — dysfunction of peripheral blood dendritic cells and T cells

Akiyama

Odagiri

Imai

et al. 1998

Japanese Journal of Rheumatology

View full text Add to dashboard Cite

Decreased concanavalin A-stimulated T cell proliferation in patients with Sjögren’s syndrome — dysfunction of peripheral blood dendritic cells and T cells

Akiyama

Odagiri

Imai

et al. 1998

Japanese Journal of Rheumatology

View full text Add to dashboard Cite

Abstract--We measured the concanavalin A (Con A)-stimulated T cell responses that were mediated by peripheral blood dendritic cells (PBDCs) obtained from patients with Sjtigren's syndrome (SS) and from normal subjects. The response to Con A responses was significantly decreased in the SS patients, as compared with the normal controls. A dysfunction of PBDCs and T cells was considered to be the cause of the decreased Con A responses. Cluster formation was investigated in the SS patients and the controls. Clusters formed in the patients with SS were smaller and less numerous than those in the controls.

show abstract

Dendritic cell dysfunction as accessory cell in patients with rheumatoid arthritis.

Cited by 3 publications

References 17 publications

Outline of Salivary Gland Pathogenesis of Sjögren’s Syndrome and Current Therapeutic Approaches

Outline of Salivary Gland Pathogenesis of Sjögren’s Syndrome and Current Therapeutic Approaches

Decreased concanavalin A-stimulated T cell proliferation in patients with Sjögren’s syndrome — dysfunction of peripheral blood dendritic cells and T cells

Decreased concanavalin A-stimulated T cell proliferation in patients with Sjögren’s syndrome — dysfunction of peripheral blood dendritic cells and T cells

Contact Info

Product

Resources

About